Rhythm Pharmaceuticals, Inc. (RYTM), a Boston-based commercial-stage biopharmaceutical company focused on rare genetic diseases of obesity, carries a near-unanimously bullish sell-side view. For this analysis, the central target is derived from the seven most recent, individually attributed analyst targets published after the company's third-quarter report in early November 2026. Those targets are: Canaccord Genuity's Whitney Ijem at $168, Citizens' Jonathan Wolleben at $166, Wells Fargo at $155, Guggenheim's Seamus Fernandez at $147, Morgan Stanley's Michael Ulz at $146, Citi's Samantha Semenkow at $143, and JPMorgan's Priyanka Grover at $142.
These seven range from $142 to $168 and average approximately $152, which rounds to a $150 central target. For context, independent aggregators that fold in targets not recently revised report a lower consensus near $140 (S&P Global, 19 analysts, range $112 to $168; FactSet, 18 analysts, near $142). The wide spread reflects genuine disagreement: some analysts weight the near-term commercial ramp of the lead drug, while others discount further out for pipeline and cash-burn uncertainty. The $150 figure here is a calculated mean, not an official published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Shares recently traded near $114, giving Rhythm a market capitalization of roughly $7.9 billion. Reaching $150 would require a gain of about 32% from current levels — a substantial move that would push the stock decisively through its 52-week high of $122.20. The path depends heavily on execution rather than valuation expansion: the company is not yet profitable on a GAAP (generally accepted accounting principles) basis, so investors are paying for future growth of IMCIVREE and the broader melanocortin-4 receptor (MC4R) franchise.
Trailing-twelve-month revenue is about $281 million, and the business has been growing quickly as IMCIVREE (setmelanotide) expands into acquired hypothalamic obesity and additional geographies. Sequential product sales rose roughly 19% in the most recent quarter, supporting the view that commercial traction is broadening beyond initial prescriptions into recurring reimbursed demand.
The stock's 52-week range spans $74.50 to $122.20. The $122 area marks a key resistance zone and prior high that would need to be cleared for any move toward $150. On the downside, recent trading established support in the $103–$105 zone, with a secondary shelf near the $112–$115 region. A decisive breakout above $122, ideally on volume, would be a meaningful technical confirmation, while a slide below $103 could signal renewed selling pressure.
Most analyst price targets reflect a roughly 12-month research horizon, though individual methodologies differ. Upcoming items most relevant to the target include quarterly earnings and guidance, IMCIVREE prescription and reimbursement trends, updates on RM-718 tolerability and development, and progress on international launches. Regulatory decisions, payer coverage changes, and any financing announcements also matter given the company's cash-burn profile. Investors should watch for analyst target revisions as a signal of shifting sentiment rather than as a forecast of a specific price.
I often turn to Tickeron’s AI Daily Buy/Sell Signals as a quick way to layer data-driven insights onto fundamental research. These signals scan thousands of stocks and ETFs in real time, highlighting potential shifts based on technical patterns and market conditions. For names like RYTM that sit in a high-growth but unprofitable sector, they can help flag momentum changes that might not be immediately obvious from earnings releases alone. This approach keeps the analysis grounded without replacing traditional due diligence.
The question of whether RYTM can reach $150 hinges on sustained commercial execution rather than a single catalyst. The target, an average of seven recent analyst views spanning $142 to $168, sits about 32% above the current price and above the broader ~$140 consensus that includes older targets. Support comes from accelerating IMCIVREE revenue, label and geographic expansion, and encouraging RM-718 data. The principal obstacles are ongoing losses, cash-burn and dilution risk, slow patient diagnosis, and RM-718 tolerability. Because the stock is unprofitable, its value rests on growth expectations that can shift quickly with each earnings report and pipeline update. No outcome is guaranteed, and the wide target range underscores genuine disagreement about how quickly the rare-obesity opportunity converts into durable profits.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for RYTM crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on RYTM as a result. In 62 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for RYTM just turned positive on October 20, 2026. Looking at past instances where RYTM's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
RYTM moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where RYTM advanced for three days, in 236 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The 10-day RSI Indicator for RYTM moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 24 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for RYTM moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RYTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
RYTM broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RYTM entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. RYTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RYTM's P/B Ratio (75.068) is slightly higher than the industry average of (3.592). P/E Ratio (-35.987) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (27.548) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of peptide therapeutics for metabolic diseases
Industry Biotechnology